Direkt zum Inhalt
Merck
  • In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes.

In vivo biodistribution of platinum-based drugs encapsulated into multi-walled carbon nanotubes.

Nanomedicine : nanotechnology, biology, and medicine (2014-02-04)
Jian Li, Aakansha Pant, Chee Fei Chin, Wee Han Ang, Cécilia Ménard-Moyon, Tapas R Nayak, Dan Gibson, Sundara Ramaprabhu, Tomasz Panczyk, Alberto Bianco, Giorgia Pastorin
ZUSAMMENFASSUNG

Carbon nanotubes (CNTs) are promising drug delivery systems due to their external functionalizable surface and their hollowed cavity that can encapsulate several bioactive molecules. In this study, the chemotherapeutic drug cisplatin or an inert platinum(IV) complex were entrapped inside functionalized-multi-walled-CNTs and intravenously injected into mice to investigate the influence of CNTs on the biodistribution of Pt-based molecules. The platinum levels in vital organs suggested that functionalized-CNTs did not affect cisplatin distribution, while they significantly enhanced the accumulation of Pt(IV) sample in some tissues (e.g. in the lungs, suggesting their potential application in lung cancer therapy) and reduced both kidney and liver accumulation (thus decreasing eventual nephrotoxicity, a typical side effect of cisplatin). Concurrently, CNTs did not induce any intrinsic abnormal immune response or inflammation, as confirmed by normal cytokine levels and histological evaluations. Therefore, functionalized nanotubes represent an efficient nano-carrier to improve accumulation of Pt species in targeted tissues/organs. From the clinical editor: In this preclinical study functionalized carbon nanotubes are reported to be safe and efficient for targeted delivery of platinum-containing compounds in rodents. Approaches like this may improve the treatment of specific cancers, since platinum based chemotherapies are commonly used, yet limited by toxicity and relatively poor target tissue concentration.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Salpetersäure, ACS reagent, 70%
Sigma-Aldrich
Salpetersäure, 70%, purified by redistillation, ≥99.999% trace metals basis
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, 36.5-38% in H2O
SAFC
Formaldehyd -Lösung, contains 10-15% methanol as stabilizer, 37 wt. % in H2O
Sigma-Aldrich
Salpetersäure, puriss. p.a., reag. ISO, reag. Ph. Eur., for determinations with dithizone, ≥65%
Sigma-Aldrich
Salpetersäure, puriss. p.a., 65.0-67.0%
Sigma-Aldrich
Formaldehyd -Lösung, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
cis-Diamminplatin(II)-dichlorid, crystalline
Sigma-Aldrich
Salpetersäure, red, fuming, HNO3 >90 %
Sigma-Aldrich
Salpetersäure, puriss. p.a., ≥65% (T)
Sigma-Aldrich
Tetramethylammoniumhydroxid -Lösung, 25 wt. % in H2O
Supelco
Formaldehyd -Lösung, stabilized with methanol, ~37 wt. % in H2O, certified reference material
Sigma-Aldrich
2,2′-(Ethylendioxy)diethylamin, 98%
Sigma-Aldrich
Formaldehyd -Lösung, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
cis-Diaminplatin(II)-dichlorid, ≥99.9% trace metals basis
Sigma-Aldrich
Salpetersäure, ACS reagent, ≥90.0%
Supelco
Salpetersäure-Konzentrat, 0.1 M HNO3 in water (0.1N), eluent concentrate for IC
Sigma-Aldrich
Tetramethylammoniumhydroxid -Lösung, 25 wt. % in methanol
Sigma-Aldrich
Tetramethylammoniumhydroxid -Lösung, ACS reagent
Sigma-Aldrich
Tetramethylammoniumhydroxid -Lösung, 10 wt. % in H2O
Sigma-Aldrich
Formaldehyd -Lösung, tested according to Ph. Eur.
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Trimethylphenylammoniumhydroxid -Lösung, ~25% in H2O (1.68 M)
Sigma-Aldrich
trans-Platin(II)diammindichlorid
Supelco
Trimethylphenylammoniumhydroxid -Lösung, ~0.5 M (CH3)3N(OH)C6H5 in methanol, for GC derivatization, LiChropur
Sigma-Aldrich
Formaldehyd-12C -Lösung, 20% in H2O, 99.9 atom % 12C
Sigma-Aldrich
Salpeter-14N-Säurelösung, ~10 N in H2O, 99.99 atom % 14N
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Cisplatin Unreinheit A, European Pharmacopoeia (EP) Reference Standard